This week we look at the Food and Drug Administration’s approval of an over-the-counter naloxone nasal spray, promising vaccines nearing approval to treat respiratory syncytial virus, and the FDA’s new guidance on diversity considerations for later-stage clinical trials. We also look at a new ... READ MORE >
life sciences
5 things to know in life sciences: Week of Feb. 6, 2023
This week we look at the President’s State of the Union Address and his support to reduce drug prices, a concerning drug shortage in European countries, and a new brain-computer interface company that raised $41 million. We also review the recent acquisition of Cardiovascular Systems by Abbott. Finally, ... READ MORE >
5 things to know in life sciences: Week of Jan. 30, 2023
This week we look at how start-ups are rethinking how clinical trials are designed and managed to improve efficiency and accuracy. We also examine biosimilar versions of a blockbuster biologic, what to expect for cell and gene therapy companies, and why the U.S. government may pay lower prices after ... READ MORE >
5 things to know in life sciences: Week of Jan. 23, 2023
This week we look at an emerging funding source within biotechs, the hottest topics during the recent JP Morgan Healthcare Conference, a revolutionary app to automate insulin dosing, the struggle for Medicare reimbursement of obesity drugs, and the Food and Drug Administration’s final guidance on ... READ MORE >
5 things to know in life sciences: Week of Jan. 16, 2023
This week we look at growing pharmaceutical manufacturing investment, the potential for a biotech recovery in 2023, discussion about the future home of the JP Morgan Healthcare Conference, U.S. biopharma wins in the Chinese market, and the future of the Johnson & Johnson COVID-19 vaccine. Each week ... READ MORE >
5 things to know in life sciences: Week of Jan. 9, 2023
This week we look at proposed pricing increases for the Moderna COVID-19 vaccine, changes in the private equity landscape for biopharma and strategic announcements from Pfizer. We also highlight remarks from the Food and Drug Administration commissioner at the JP Morgan conference and major commitment in ... READ MORE >
5 things to know in life sciences: Week of Dec. 19, 2022
It has been quite the year in life sciences as we try to define a new normal following the pandemic. While funding struggled, breakthroughs abounded. In addition, the Food and Drug Administration continued its work on drug pricing and clinical trial diversity. We can’t capture it all in one article, but ... READ MORE >
5 things to know in life sciences: Week of Dec. 12, 2022
This week we look at the doctors creating a personalized medicine to help a specific patient who had exhausted all other options. We also highlight options for using data to support Medicare drug pricing negotiation, large scale DNA sequencing projects in infants, and efforts to use genome sequencing to ... READ MORE >
5 things to know in life sciences: Week of Dec. 5, 2022
This week we look at the Food and Drug Administration’s vaccine activity related to RSV and COVID-19, mRNA opportunities to treat cancer, diversity in clinical trials, and a large in-licensing deal highlighting the industry’s recent move away from traditional funding sources. Each week we highlight ... READ MORE >
5 things to know in life sciences: Week of Nov. 28, 2022
This week we look at mRNA technology that could be used in a universal flu vaccine, the rise in digital therapies despite a lack of insurance coverage, and another drug breaking the record for most expensive in the world. We also look at a new Centers for Disease Control and Prevention program to monitor ... READ MORE >